Hives, or what doctors call urticaria, are red, itchy, and sometimes painful welts that show up on your skin. If you have chronic spontaneous urticaria (CSU), your hives occur spontaneously and recur ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted an opinion recommending the approval of ...
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...
In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...
TipRanks on MSN
Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion
An announcement from Sanofi ( ($SNY) ) is now available. On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a ...
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in the ...
Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback